ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.77
-1.09%
US Tech 100
20,778.00
-0.69%
S&P 500
6,040.53
-0.50%
US Dollar vs CAD
1.47242
0.07%
Bitcoin
95,143.10
-2.63%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU

  6. Inventiva (IVA) Share Price

Inventiva

Inventiva (IVA)

Inventiva SA
2.325
0.01
(0.43%)
Closed February 02 10:30AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
2.325
Bid
2.315
Ask
2.335
Volume
19,042
2.30 Day's Range 2.38
1.434 52 Week Range 4.30
Market Cap
489.81M
Previous Close
2.315
Open
2.38
Last Trade
30
@
2.325
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
23,798
Shares Outstanding
210,670,845
Dividend Yield
-
PE Ratio
-4.43
Earnings Per Share (EPS)
-0.52
Revenue
23.16M
Net Profit
-110.43M

About Inventiva

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.inventivapharma.com
Headquarters
Daix, Fra
Founded
-
Inventiva is listed in the Biological Pds,ex Diagnstics sector of the Euronext with ticker IVA. The last closing price for Inventiva was 2.32 €. Over the last year, Inventiva shares have traded in a share price range of 1.434 € to 4.30 €.

Inventiva currently has 210,670,845 shares outstanding. The market capitalization of Inventiva is 487.70 € million. Inventiva has a price to earnings ratio (PE ratio) of -4.43.

Ask ADVFN Intelligence (AI)

IVA Latest News

More News

Inventiva annonce la publication dans la revue « Journal of Hepatology » des résultats de l’étude clinique de preuve de concept initiée par un investigateur évaluant lanifibranor chez des patients atteints de DT2 et MASLD

Inventiva annonce la publication dans la revue « Journal of Hepatology » des résultats de l’étude clinique de preuve de concept initiée par un investigateur évaluant lanifibranor chez des patients...

January 29 2025
UK Regulatory

Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology

Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of...

January 29 2025
UK Regulatory

Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology

As previously reported1, the study met the primary efficacy endpoint for the treatment with lanifibranor 800mg demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance...

January 29 2025
GlobeNewswire Inc.

Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux

Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux Daix (France), New York City (New York, Etats-Unis), le 24 janvier 2025 – Inventiva (Euronext Paris...

January 24 2025
UK Regulatory

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Daix (France), New York City (New York, United States), January 24, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company...

January 24 2025
GlobeNewswire Inc.

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Daix (France), New York City (New York, United States), January 24, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA...

January 24 2025
UK Regulatory

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025 Daix (France), New York City (New York...

January 22 2025
UK Regulatory

Résultats de LEGEND évaluant la combinaison de lanifibranor avec empagliflozine dans la MASH ont été sélectionnés pour présentation orale au EASL SLD Summit 2025

Résultats de LEGEND évaluant la combinaison de lanifibranor avec empagliflozine dans la MASH ont été sélectionnés pour présentation orale au EASL SLD Summit 2025 Daix (France), New York City (New...

January 22 2025
UK Regulatory

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025

Daix (France), New York City (New York, United States), January 22, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company...

January 22 2025
GlobeNewswire Inc.

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference

Daix (France), New York City (New York, United States), December 17, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the...

December 17 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.185-7.370517928292.512.512.155421562.26727383DE
40.2059.669811320752.122.7052.11295572.33451687DE
12-0.075-3.1252.42.7052237982.34899615DE
260.0954.26008968612.233.21.434384512.28550203DE
52-1.22-34.41466854723.5454.31.434456782.78812641DE
156-8.375-78.271028037410.7121.434538293.71969872DE
260-1.595-40.68877551023.9216.31.434627817.10899455DE

IVA - Frequently Asked Questions (FAQ)

What is the current Inventiva share price?
The current share price of Inventiva is 2.325 €
How many Inventiva shares are in issue?
Inventiva has 210,670,845 shares in issue
What is the market cap of Inventiva?
The market capitalisation of Inventiva is EUR 487.7M
What is the 1 year trading range for Inventiva share price?
Inventiva has traded in the range of 1.434 € to 4.30 € during the past year
What is the PE ratio of Inventiva?
The price to earnings ratio of Inventiva is -4.43
What is the cash to sales ratio of Inventiva?
The cash to sales ratio of Inventiva is 21.11
What is the reporting currency for Inventiva?
Inventiva reports financial results in EUR
What is the latest annual turnover for Inventiva?
The latest annual turnover of Inventiva is EUR 23.16M
What is the latest annual profit for Inventiva?
The latest annual profit of Inventiva is EUR -110.43M
What is the registered address of Inventiva?
The registered address for Inventiva is 50 RUE DE DIJON, DAIX, 21121
What is the Inventiva website address?
The website address for Inventiva is www.inventivapharma.com
Which industry sector does Inventiva operate in?
Inventiva operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ALCYBCybergun
0.0002 €
(100.00%)
63.2M
TUVDSBio UV Group DS
0.015 €
(70.45%)
490.92k
CANDCandela Invest
1.70 €
(70.00%)
42
BIODSBiosynex DS
0.07 €
(39.44%)
55.52k
ALGTRGroupe Tera SA
4.10 €
(25.77%)
17.71k
MLIMLImalliance
0.282 €
(-27.32%)
1.5k
ALCARCarmat
0.822 €
(-22.60%)
3.04M
MLOCTOctopus Biosafety
0.14 €
(-21.35%)
18.55k
ALEXPOne Experience
0.386 €
(-21.22%)
933
SNGSonagi
0.80 €
(-20.00%)
800
ATOAtos SE
0.0023 €
(4.55%)
608.11M
ALVERVergnet
0.0011 €
(0.00%)
92.88M
ALCYBCybergun
0.0002 €
(100.00%)
63.2M
BCPBanco Comercial Portugues SA
0.5054 €
(0.04%)
32.95M
KPNKoninklijke KPN NV
3.491 €
(-1.77%)
16.54M

Discussion

View Full Feed
georgejjl georgejjl 2 minutes ago
Expect Anavex Life Sciences To Report Fiscal 2025 First Quarter Financial Results and Provides Business Update THIS WEEK!!!

Good luck and GOD bless,
AVXL
3331 3331 3 minutes ago
BIEL #2 STOCK BREAKOUT BOARD, +50% GOLDEN CROSS BREAKOUT, 911 NEWS PENDING!
Kimbrown Kimbrown 5 minutes ago
Shorties take every chance to hammer it. But we are at the end of tunnel to see light.
FNMA
delerious1 delerious1 5 minutes ago
10 %....more like 30%
XRPUSD
Sharp Shooter Sharp Shooter 6 minutes ago
These two post didn't age well !
BDPT
OMOLIVES OMOLIVES 7 minutes ago
Who told you that?
955 955 8 minutes ago
Absolutely SHOCKED they run operations with such tight tolerances, no matter how good the instrumentation. No room whatsoever for error. That blackhawk had no business flying through airport airspace. Let alone at night on a training mission no less. Reckless endangerment of life. Common sense
marcis marcis 8 minutes ago
I agree with you

Not a big thing to load before news and cash huge
DRGV
RealDutch RealDutch 9 minutes ago
Banks should be open in Hong Kong. This will be an important week.
ITUP
navycmdr navycmdr 10 minutes ago
so ... if we dip below $5 no matter ... - $BUY $BUY $BUY !
BUY
marcis marcis 10 minutes ago
Yes very true
But it’s all speculation at this point

I truly believe 2026 new Sec chair Trump era is going to open things up wide for investors
DRGV
littlejohn littlejohn 11 minutes ago
Trumpenburg and short Associates are happy...

He will look silly asking FED not

to raise rates after he added 25%

inflation on items from Canada and

from Mexico...

1% over night isn't even a good starting

drop
dragoon76 dragoon76 11 minutes ago
What?? Useless nonsensical dribble like WMIH merging with Dell, Microsoft, etc.
RD is a different kind of basher/disrupter
COOP
CanItBThisEZ2Make CanItBThisEZ2Make 12 minutes ago
The BG96 is Available is Only Available on the Tri Cascade Inc Website --->
https://investorshub.advfn.com/uimage/uploads/2025/2/2/kgntmBG96.png
https://www.tricascadeinc.com/bg96
https://www.tricascadeinc.com/_files/ugd/3c10e2_8f9dc0523f0e468ca05a3e4015ede0a8.pdf

SRMX
fuagf fuagf 12 minutes ago
Don't worry Donald we have Russia covered no matter what position you publicly take. Either 'i really respect him' friend, or great dealmaker 'i'll finish the war in a day', or tough 'if he doesn't take the peace deal i'll hit him with more sanctions, tariffs' tough guy talk which is great for you
jcromeenes jcromeenes 12 minutes ago
Futures say the market's reaction to the tariffs is going to be really bloody. Monday is going to be red, red, red.
FNMA
dukeb dukeb 12 minutes ago
I'll have to get back to you on that.

don't we have to think of the two of them as one person, at least?
crazy horse 0 crazy horse 0 13 minutes ago
75% of Dems believe NYC is in crisis – and nearly half are ready to leave if things get worse: new poll

https://nypost.com/2025/02/02/us-news/new-poll-shows-75-of-dems-say-nyc-in-crisis-with-nearly-half-ready-to-leave-if-things-get-worse/?utm_campaign=iphone_nyp&utm_source=mail_app
cojoboy cojoboy 13 minutes ago
O.C..I got a plane ticket were ever you reside to flew to Syria..my treat..😍😍
CGAC
trade2brich trade2brich 14 minutes ago
What are you trying to say? Obvi there could be a buyout but at rock bottom pps then useless. I do not at all see or read of a strong management team. Again, same story as every other otc stock. 
SHOT
BeachBum BeachBum 14 minutes ago
Work it! lol
PSRU
Iggy_Bot Iggy_Bot 15 minutes ago
obama, i mean biden sure left one hell of a mess for Trump
4retire 4retire 15 minutes ago
It is my opinion that DeepSeek will turn out to be the same as the Israelis supplying pagers to Hezbollah
NVDA
DrivenByPain DrivenByPain 16 minutes ago
February 11/2025 Will be 9 Months .
SGDH
dukeb dukeb 16 minutes ago
The major news outlets made a calculated decision to sanewash the whacked out sh*t that Drumpf said during the campaign while holding a microscope to everything that Kamala said or did.

And they did it because...ratings. The media doesn't want calm and steady hands controlling the go

Your Recent History

EU
IVA
Inventiva
BIT
NSCIT0554740
Italy
BIT
UC5SZQ
Unicredit Bank
BIT
W9SPZ4
UBS
BIT
UC84CV
Unicredit Bank
BIT
BIM
Banca Intermobiliare
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads